SRSF3: A Potential Drug Target and Biomarker (G6428)

Target Name: SRSF3

NCBI ID: G6428

SRSF3

SRSF3: A Potential Drug Target and Biomarker

Splicing factors are important proteins that regulate the process of gene expression in eukaryotic cells. They assist in the production of functional RNA molecules by modifying pre-mRNA splicing events. SRSF3, a splice-factor subunit, is a protein that has been identified as a potential drug target and biomarker. In this article, we will discuss the SRSF3 protein, its function, potential drug targets, and its potential as a biomarker.

SRSF3: Structure and Function

SRSF3 is a 21-kDa protein that contains 115 amino acid residues. It belongs to the SRSF3 family, which is characterized by the presence of a specific domain called the N-terminal alpha-helix and a conserved C-terminal region. The N- The terminal alpha-helix is 鈥嬧?媋 structural feature that gives SRSF3 its stability and stability in various cellular processes. The C-terminal region is involved in SRSF3's interaction with other proteins.

SRSF3 is a key regulator of pre-mRNA splicing in various cell types. It has been shown to play a role in the regulation of gene expression by modifying splicing efficiency and the choice of exons. SRSF3 has been shown to interact with various protein partners, including other splice factors, non-coding RNAs, and even DNA.

Potential Drug Targets

SRSF3 is a protein that has been identified as a potential drug target due to its involvement in the regulation of pre-mRNA splicing. Many drugs that are currently in use target proteins involved in this process, such as small interfering RNA (siRNA) and long non-coding RNAs (lncRNA). SRSF3 is an attractive target for drugs because of its unique mechanism of action and its involvement in various cellular processes.

One of the potential drug targets for SRSF3 is its role in the regulation of cancer cell splicing. cancer cells often have aberrant splicing patterns that lead to the production of non-functional RNA molecules. SRSF3 has been shown to play a role in the regulation of cancer cell splicing, which may make it an attractive target for cancer therapies.

Another potential drug target for SRSF3 is its role in the regulation of neurodegenerative diseases. SRSF3 has been shown to play a role in the regulation of pre-mRNA splicing in neurotransmitter-producing neurons, which may be involved in the pathophysiology of neurodegenerative diseases. Therefore , targeting SRSF3 with drugs that can modulate its function may be a promising strategy for the development of neurodegenerative disease therapies.

Biomarkers

SRSF3 has also been identified as a potential biomarker for various diseases. One of the potential applications of SRSF3 as a biomarker is its ability to be modified and detected using various techniques, such as RNA sequencing (RNA-seq), qRT-PCR, and western blotting.

SRSF3 has been shown to be expressed in various tissues and cells, including brain, spinal cord, and peripheral tissues. It has also been shown to be involved in the regulation of pre-mRNA splicing in these tissues, which may be a potential biomarker for neurodegenerative diseases.

Another potential application of SRSF3 as a biomarker is its ability to be modified and detected using various techniques. For example, SRSF3 can be modified by the addition of fluorescent tags, which can be used to detect the protein in various tissues and cells. This may be a promising strategy for the development of diagnostic tests for neurodegenerative diseases.

Conclusion

SRSF3 is a protein that has been identified as a potential drug target and biomarker. Its unique mechanism of action and its involvement in various cellular processes make it an attractive target for drugs that can modulate its function. SRSF3 has also been shown to play a role in the regulation of cancer cell splicing and in the regulation of neurotransmitter-producing neurons, which may be involved in the pathophysiology of neurodegenerative diseases. Therefore, targeting SRSF3 with drugs that can modulate its function may be a promising strategy for

Protein Name: Serine And Arginine Rich Splicing Factor 3

Functions: Splicing factor that specifically promotes exon-inclusion during alternative splicing (PubMed:26876937). Interaction with YTHDC1, a RNA-binding protein that recognizes and binds N6-methyladenosine (m6A)-containing RNAs, promotes recruitment of SRSF3 to its mRNA-binding elements adjacent to m6A sites, leading to exon-inclusion during alternative splicing (PubMed:26876937). Also functions as export adapter involved in mRNA nuclear export (PubMed:11336712, PubMed:18364396, PubMed:28984244). Binds mRNA which is thought to be transferred to the NXF1-NXT1 heterodimer for export (TAP/NXF1 pathway); enhances NXF1-NXT1 RNA-binding activity (PubMed:11336712, PubMed:18364396). Involved in nuclear export of m6A-containing mRNAs via interaction with YTHDC1: interaction with YTHDC1 facilitates m6A-containing mRNA-binding to both SRSF3 and NXF1, promoting mRNA nuclear export (PubMed:28984244). RNA-binding is semi-sequence specific (PubMed:17036044)

The "SRSF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRSF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets